Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

NCT04723537 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

61

Enrollment

INDUSTRY

Sponsor class

Stopped Part A complete; corporate decision made to cancel Part B.

Conditions

Covid19

Interventions

DRUG: Part A: Upamostat 200 mg
DRUG: Part A: Upamostat 400 mg
DRUG: Part A and B: Placebo
DRUG: Part B: Upamostat 200 or 400 mg

Sponsor

RedHill Biopharma Limited